GERN – Geron Corporation
Float Short %
9.65
Margin Of Safety %
Put/Call OI Ratio
0.42
EPS Next Q Diff
EPS Last/This Y
0.15
EPS This/Next Y
0.09
Price
1.89
Target Price
3.4
Analyst Recom
2
Performance Q
69.37
Upside
-323.4%
Beta
0.54
Ticker: GERN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | GERN | 1.37 | 0.45 | 0.22 | 63860 |
| 2026-01-26 | GERN | 1.37 | 0.45 | 0.21 | 64012 |
| 2026-01-27 | GERN | 1.385 | 0.45 | 0.80 | 64138 |
| 2026-01-28 | GERN | 1.335 | 0.45 | 2.02 | 64216 |
| 2026-01-29 | GERN | 1.375 | 0.45 | 0.08 | 64375 |
| 2026-01-30 | GERN | 1.365 | 0.45 | 0.03 | 64918 |
| 2026-02-02 | GERN | 1.545 | 0.45 | 0.08 | 65067 |
| 2026-02-03 | GERN | 1.52 | 0.44 | 0.10 | 65920 |
| 2026-02-04 | GERN | 1.47 | 0.44 | 0.31 | 65838 |
| 2026-02-05 | GERN | 1.465 | 0.44 | 0.16 | 65908 |
| 2026-02-06 | GERN | 1.525 | 0.44 | 0.30 | 66515 |
| 2026-02-09 | GERN | 1.6 | 0.44 | 0.00 | 66718 |
| 2026-02-10 | GERN | 1.625 | 0.42 | 0.37 | 68826 |
| 2026-02-11 | GERN | 1.605 | 0.42 | 0.10 | 68805 |
| 2026-02-12 | GERN | 1.625 | 0.43 | 0.14 | 68753 |
| 2026-02-13 | GERN | 1.66 | 0.43 | 0.07 | 68313 |
| 2026-02-17 | GERN | 1.805 | 0.42 | 0.02 | 69158 |
| 2026-02-18 | GERN | 1.945 | 0.41 | 0.07 | 70343 |
| 2026-02-19 | GERN | 1.925 | 0.41 | 0.11 | 71222 |
| 2026-02-20 | GERN | 1.885 | 0.42 | 0.13 | 70545 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | GERN | 1.37 | -26.4 | 43.8 | -0.12 |
| 2026-01-26 | GERN | 1.37 | -26.4 | 43.8 | -0.12 |
| 2026-01-27 | GERN | 1.38 | -26.4 | 43.7 | -0.12 |
| 2026-01-28 | GERN | 1.35 | -26.4 | 43.8 | -0.12 |
| 2026-01-29 | GERN | 1.37 | -26.4 | 43.6 | -0.12 |
| 2026-01-30 | GERN | 1.36 | -26.4 | 43.7 | -0.12 |
| 2026-02-02 | GERN | 1.54 | -26.4 | 43.3 | -0.12 |
| 2026-02-03 | GERN | 1.52 | -26.4 | 43.8 | -0.12 |
| 2026-02-04 | GERN | 1.47 | -26.4 | 43.8 | -0.12 |
| 2026-02-05 | GERN | 1.47 | -26.4 | 43.7 | -0.12 |
| 2026-02-06 | GERN | 1.52 | -26.4 | 43.6 | -0.12 |
| 2026-02-09 | GERN | 1.61 | -26.4 | 43.6 | -0.12 |
| 2026-02-10 | GERN | 1.62 | -26.4 | 43.7 | -0.12 |
| 2026-02-11 | GERN | 1.61 | -26.4 | 43.7 | -0.12 |
| 2026-02-12 | GERN | 1.63 | -26.4 | 43.7 | -0.12 |
| 2026-02-13 | GERN | 1.65 | -26.4 | 43.7 | -0.12 |
| 2026-02-17 | GERN | 1.80 | -26.4 | 43.5 | -0.12 |
| 2026-02-18 | GERN | 1.95 | -26.4 | 43.5 | -0.12 |
| 2026-02-19 | GERN | 1.93 | -26.4 | - | -0.12 |
| 2026-02-20 | GERN | 1.89 | -26.4 | - | -0.12 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | GERN | 0.00 | -2.80 | 11.73 |
| 2026-01-26 | GERN | 0.00 | -2.12 | 11.73 |
| 2026-01-27 | GERN | 0.00 | -2.12 | 11.73 |
| 2026-01-28 | GERN | 0.00 | -2.12 | 11.60 |
| 2026-01-29 | GERN | 0.00 | -2.12 | 11.60 |
| 2026-01-30 | GERN | 0.00 | -2.12 | 11.60 |
| 2026-02-02 | GERN | 0.00 | -2.09 | 11.60 |
| 2026-02-03 | GERN | 0.00 | -2.09 | 11.60 |
| 2026-02-04 | GERN | 0.00 | -2.09 | 11.60 |
| 2026-02-05 | GERN | 0.00 | -2.09 | 11.60 |
| 2026-02-06 | GERN | 0.00 | -2.09 | 11.60 |
| 2026-02-09 | GERN | 0.00 | -1.71 | 11.60 |
| 2026-02-10 | GERN | 0.00 | -1.71 | 11.60 |
| 2026-02-11 | GERN | 0.00 | -1.71 | 9.62 |
| 2026-02-12 | GERN | 0.00 | -1.71 | 9.62 |
| 2026-02-13 | GERN | 0.00 | -1.71 | 9.62 |
| 2026-02-17 | GERN | 0.00 | 2.35 | 9.61 |
| 2026-02-18 | GERN | 0.00 | 2.35 | 9.61 |
| 2026-02-19 | GERN | 0.00 | 2.35 | 9.61 |
| 2026-02-20 | GERN | -0.03 | 2.35 | 9.65 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.03
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.03
Insider Transactions
-0.03
Institutional Transactions
2.35
Beta
0.54
Average Sales Estimate Current Quarter
50
Average Sales Estimate Next Quarter
51
Fair Value
Quality Score
48
Growth Score
55
Sentiment Score
62
Actual DrawDown %
64.6
Max Drawdown 5-Year %
-79
Target Price
3.4
P/E
Forward P/E
PEG
P/S
6.54
P/B
4.83
P/Free Cash Flow
EPS
-0.12
Average EPS Est. Cur. Y
-0.12
EPS Next Y. (Est.)
-0.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-43.61
Relative Volume
2.41
Return on Equity vs Sector %
-61.2
Return on Equity vs Industry %
-43.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Geron CorporationSector: Healthcare
Industry: Biotechnology
Employees: 229
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
stock quote shares GERN – Geron Corporation Stock Price stock today
news today GERN – Geron Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GERN – Geron Corporation yahoo finance google finance
stock history GERN – Geron Corporation invest stock market
stock prices GERN premarket after hours
ticker GERN fair value insiders trading